TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究

doi:10.11904/j.issn.1002-3070.2024.06.008

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (6): 402-409.doi: 10.11904/j.issn.1002-3070.2024.06.008

TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究

庞琬莹, 安静, 刘兆良

哈尔滨医科大学肿瘤防治研究所(哈尔滨 150081)

收稿日期:2024-09-27 修回日期:2024-11-16 出版日期:2024-12-28 发布日期:2025-01-06
通讯作者: 刘兆良,E-mail:zliu_hrbmu@163.com
作者简介:庞琬莹,女,(2000-),硕士研究生,从事肿瘤耐药机制的研究。
基金资助:
黑龙江省自然科学基金联合引导项目(编号:LH2021H058)

The role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer

PANG Wanying, AN Jing, LIU Zhaoliang

Institute of Cancer Prevention and Treatment,Harbin Medical University,Harbin 150081,China

Received:2024-09-27 Revised:2024-11-16 Online:2024-12-28 Published:2025-01-06

摘要/Abstract

摘要： 目的探讨TRIM24在乳腺癌内分泌治疗耐药中的调控作用及作用机制。方法通过Kaplan-Meier Plotter数据库分析接受内分泌治疗的乳腺癌患者中TRIM24表达与预后的关系。使用他莫昔芬(Tamoxifen,TAM)处理乳腺癌细胞MCF7或T47D后,应用qRT-PCR及Western blot法检测TRIM24的表达。在TAM敏感细胞MCF7/S0.5和耐药细胞MCF7/TAMR-1中敲除TRIM24后,CCK-8法检测细胞增殖情况。在MCF7细胞中敲除雌激素受体(Estrogen receptor,ER)或使用选择性孕酮受体(Progesterone receptor,PR)拮抗剂醋酸乌利司他(Ulipristal acetate,UPA)处理后,通过qRT-PCR及Western blot法检测TRIM24的表达情况。在MCF7中过表达PR后,Western blot法检测TRIM24的表达变化。过表达TRIM24后通过qRT-PCR及Western blot法检测人表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)的表达。结果在接受内分泌治疗的乳腺癌患者中,TRIM24高表达患者的无复发生存期(Recurrence free survival,RFS)更短(P=0.027)。TAM处理能够诱导TRIM24表达升高(P＜0.001)。敲除TRIM24可以显著抑制耐药细胞MCF7/TAMR-1的增殖(P＜0.001),而对敏感细胞MCF7/S0.5没有影响。敲除ER或使用PR拮抗剂处理后能够上调TRIM24的表达(P＜0.01),而过表达PR后能够下调TRIM24的表达。TRIM24可以激活HER2表达(P＜0.05)。结论 PR负调控TRIM24在乳腺癌内分泌治疗耐药中发挥重要作用。

关键词: TRIM24, 他莫昔芬, 孕激素受体, 内分泌治疗耐药

Abstract: Objective The aim of this study was to investigate the regulatory role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer. Methods The relationship between TRIM24 expression and prognosis in breast cancer patients receiving endocrine therapy was analyzed by the Kaplan-Meier Plotter database.After treatment of breast cancer MCF7 cells or T47D cells with tamoxifen(TAM),the expression of TRIM24 was detected by qRT-PCR and Western blot.After knocking out TRIM24 in TAM sensitive MCF7/S0.5 cells and resistant cells MCF7/TAMR-1 cells,cell proliferation was measured by CCK 8 assay.After knocking out the estrogen receptor(ER)or treating with the selective progesterone receptor(PR)antagonist UPA(Ulipristal acetate)in MCF7 cells,the expression of TRIM24 was measured by qRT-PCR and Western blot.After PR was overexpressed in MCF7 cells,the expression of TRIM24 was detected by Western blot.The expression of human epidermal growth factor receptor 2(HER2)was detected by qRT PCR and Western blot after the overexpression of TRIM24. Results Among breast cancer patients receiving endocrine therapy,patients with high expression of TRIM24 had a shorter recurrence free survival(RFS)(P=0.027).TAM treatment could induce an increase of TRIM24 expression(P＜0.001);Knocking out TRIM24 significantly inhibited the proliferation of drug-resistant MCF7/TAMR-1 cells(P＜0.001),but had no effect on sensitive MCF7/S0.5 cells;After knocking out ER or treatment of PR antagonist,the expression of TRIM24 could be upregulated in MCF7 cells(P＜0.01),while overexpression of PR could down-regulate the expression of TRIM24.TRIM24 could activate the expression of HER2(P＜0.05). Conclusion PR negatively regulation of TRIM24 plays an important role in endocrine therapy resistance of breast cancer.

Key words: TRIM24, Tamoxifen, Progesterone receptor, Endocrine therapy resistance

中图分类号:

R737.9

庞琬莹, 安静, 刘兆良. TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究[J]. 实用肿瘤学杂志, 2024, 38(6): 402-409.

PANG Wanying, AN Jing, LIU Zhaoliang. The role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer[J]. Journal of Practical Oncology, 2024, 38(6): 402-409.

参考文献

1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
2 Nolan E,Lindeman GJ,Visvader JE.Deciphering breast cancer:from biology to the clinic[J].Cell,2023,186(8):1708-1728.
3 Burstein HJ.Systemic therapy for estrogen receptor-positive,HER2-negative breast cancer[J].N Engl J Med,2020,383(26):2557-2570.
4 Ali S,Rasool M,Chaoudhry H,et al.Molecular mechanisms and mode of tamoxifen resistance in breast cancer[J].Bioinformation,2016,12(3):135-139.
5 Ferrando L,Vingiani A,Garuti A,et al.ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing hormone receptor-positive,HER2-negative breast cancer(HR+ HER2-BC)[J].PLoS Genet,2023,19(1):e1010563.
6 Nayar U,Cohen O,Kapstad C,et al.Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies[J].Nat Genet,2019,51(2):207-216.
7 Li H,Prever L,Hirsch E,et al.Targeting PI3K/AKT/mTOR signaling pathway in breast cancer[J].Cancers(Basel),2021,13(14):3517.
8 Garcia-Martinez L,Zhang Y,Nakata Y,et al.Epigenetic mechanisms in breast cancer therapy and resistance[J].Nat Commun,2021,12(1):1786.
9 Yu S,Wu R,Si Y,et al.Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer[J].Oncogene,2024,43(39):2901-2913.
10 Yuan J,Yang L,Li Z,et al.The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer[J].Front Endocrinol(Lausanne),2023,14:1261283.
11 Miao ZF,Wang ZN,Zhao TT,et al.TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance[J].Virchows Arch,2015,466(5):525-532.
12 Zhang L,Chen H,Ding B,et al.High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer[J].J Ovarian Res,2022,15(1):19.
13 Zhang LH,Yin AA,Cheng JX,et al.TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway[J].Oncogene,2015,34(5):600-610.
14 Ma L,Yuan L,An J,et.al.Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer[J].Tumor Biol,2016,37(11):14803-14812.
15 Shah VV,Duncan AD,Jiang S,et al.Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer[J].Nat Commun,2021,12(1):5389.
16 Sanjana NE,Shalem O,Zhang F.Improved vectors and genome-wide libraries for CRISPR screening[J].Nat Methods,2014,11(8):783-784.
17 Sahai V,Redig AJ,Collier KA,et al.Targeting BET bromodomain proteins in solid tumors[J].Oncotarget,2016,7(33):53997-54009.
18 Xu Y,Vakoc CR.Targeting cancer cells with BET bromodomain inhibitors[J].Cold Spring Harb Perspect Med,2017,7(7):26674.
19 Lv D,Li Y,Zhang W,et al.TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma[J].Nat Commun,2017,8(1):1454.
20 Xiang Q,Luo G,Zhang C,et al.Discovery,optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors[J].Eur J Med Chem,2022,236:114311.
21 Zhu Y,Zhao L,Shi K,et al.TRIM24 promotes hepatocellular carcinoma progression via AMPK signaling[J].Exp Cell Res,2018,367(2):274-281.
22 Xie W,Zhang Y,Wang B,et al.Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling[J].Cancer Med,2020,9(17):6367-6376.
23 Bergamaschi A,Katzenellenbogen BS.Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance[J].Oncogene,2012,31(1):39-47.
24 Godbole M,Chandrani P,Gardi N,et al.MiR-129-2 mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells[J].Cancer Biol Ther,2017,18(10):801-805.
25 Wei S.Hormone receptors in breast cancer:an update on the uncommon subtypes[J].Pathol Res Pract,2023,250:154791.
26 Campbell EJ,Tesson M,Doogan F,et al.The combined endocrine receptor in breast cancer,a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone[J].Br J Cancer,2016,115(8):967-973.

[1]	杨闽叶, 鲜童丞, 刘景建, 别俊, 王杰, 罗义. IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性[J]. 实用肿瘤学杂志, 2024, 38(5): 323-329.
[2]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[3]	于飞, 胡晶(综述), 陈雪松(审校). 乳腺癌他莫昔芬耐药机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 160-164.
[4]	王泽涛, 吕付龙, 王劲松. 自噬通过p38/c-Jun信号通路促进乳腺癌细胞对他莫昔芬耐药的研究[J]. 实用肿瘤学杂志, 2015, 29(1): 22-28.
[5]	仲崇明, 周彦, 卞光荣, 孙志超, 贾惠英, 鲁凯, 姚壮凯. 乳腺癌患者血清肿瘤标志物与免疫组化标志物相关性的研究[J]. 实用肿瘤学杂志, 2010, 24(3): 224-226.
[6]	郭文斌;刘玉忠;贾友鹏;王海波;徐梦. 环孢霉素A联合他莫昔芬对大肠癌耐药逆转的研究[J]. 实用肿瘤学杂志, 2004, 18(06): 430-431.
[7]	安天义;吕振涛;马世英;曹建平;刘民培. 乳腺癌组织中SC3A抗原、ER和PR表达及意义[J]. 实用肿瘤学杂志, 2002, 16(02): 117-119,.
[8]	熊晓平;陈修己. 胃癌雌、孕激素受体和nm23基因表达及临床意义的研究[J]. 实用肿瘤学杂志, 2002, 16(01): 38-39.
[9]	张静;梁颜笑. ER-/PR-甲状腺癌中bcl-2和c-erb-B-2癌蛋白表达及其意义[J]. 实用肿瘤学杂志, 2001, 15(02): 98-99.
[10]	史金兰;陈萍倩;林裕媛;朱明月;张蓉;赵华;薛苏华. 乳腺癌雌孕激素受体与C-erbB-2、p53、nm23基因表达及相关分析[J]. 实用肿瘤学杂志, 2001, 15(01): 10-12.

TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究

The role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价